Menu
Recruiting NCT05664035

Frequency of SPAD in Adult Patients

— Observational Specific Antibody Deficiency Predominantly Antibody Deficiencies

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Diagnosis of SPAD using immunization with PPV23.
Who it may be relevant to
Registry conditions: Specific Antibody Deficiency, Predominantly Antibody Deficiencies. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Detection of Specific Polysaccharide Antibody Deficiency in Adult Patients With Unexplained Recurrent and/or Severe Bacterial Infections

Overview

The DETECT study aims to demonstrate the importance of detecting SPAD in adult patients with recurrent benign and/or severe unexplained bacterial upper/lower respiratory tract infections. Unlike children in whom the deficit may be transient, long-term strategies are warranted in SPAD adult patients to prevent severe infections and lung disability. Beyond the diagnosis of this still unrecognized PID in adult patients, the investigators want to assess the impact of prophylactic antibiotics or IgRT on infections prevention and on quality of life in adult patients with the most severe clinical phenotypes, recurrent infections with high frequency of antibiotics take and/or recurrent infections with complications like bronchiectasis and/or severe infections requiring hospitalizations.

Detailed description

This multicenter observational prospective study will be conducted in 15 university or general hospitals, mostly centers included in the national network of the reference center CEREDIH. Pulmonologists, clinical immunologists and ENT specialists will be solicited in each center to refer patients for inclusions.

All patients who fulfill eligibility criteria will be tested for anti-pneumococcal polysaccharides (PnPSs) response with the 23-valent pneumococcal (unconjugated) vaccine (PPV23) (V1, Day 0: blood sample anti-PnPS antibodies, and immunization; V2, Day 28-56): blood sample for anti-PnPS antibodies).

If a SPAD would be diagnosed, the investigator will be free to consider prophylactic antibiotics and/or IgRT according to the medical history of the patient (notably in case of persistent infections while using prophylactic antibiotics). The efficiency on infections prevention and the impact on health-related quality of life (HRQoL) will be assessed 12 months after initiation of IgRT or prophylactic antibiotics (Visit 3).

Interventions

  • Biological Diagnosis of SPAD using immunization with PPV23
    Diagnosis of SPAD using immunization with PPV23

Primary outcome measures

  • To assess the frequency of SPAD in adult patients with unexplained recurrent bacterial respiratory infections [Time frame: 4 to 8 weeks after immunization]
Secondary outcome measures (6)
  • To describe infectious and non infectious associated diseases, including allergy and autoimmune diseases, in SPAD patients. [Time frame: Througth study completion, an average 24 months]
  • To assess the benefit of IgRT on the frequency of courses of antibiotic therapy. [Time frame: Througth study completion, an average 24 months]
  • To assess the benefit of IgRT on QoL and daily life. [Time frame: Througth study completion, an average 24 months]
  • To assess the benefit of prophylactic antibiotics on the frequency of courses of antibiotic therapy. [Time frame: Througth study completion, an average 24 months]
  • To assess the benefit of prophylactic antibiotics on QoL and daily life. [Time frame: Througth study completion, an average 24 months]
  • To collect serum and mononuclear cells for future research projects in SPAD and undiagnosed patients. [Time frame: Througth study completion, an average 24 months]

Eligibility criteria

Inclusion criteria

  • 18 to 65 year old patients
  • With a history of recurrent bacterial infections of upper and/or lower respiratory tract for at least 2 years, and fulfilling the specific following criteria:
  • Recurrent benign infections currently requiring 6 courses of antibiotics /year or more, or Bilateral bronchiectasis/bronchiolitis (after exclusion of cystic fibrosis and ciliary dyskinesia) AND recurrent benign infections currently requiring 3 courses of antibiotics /year or more or A history of severe upper/lower respiratory tract bacterial infection, and/or invasive infection with Streptococcus pneumonia, Streptococcus pyogenes or Haemophilus influenzae, which required hospitalization in the last 2 years, AND recurrent benign infections currently requiring 3 courses of antibiotics /year.
  • Normal serum IgG, IgA, IgM and IgG subclasses levels, normal CH50 and serum complement C3 and C4 proteins levels, normal T cells count
  • Normal B cell count, normal serum protein electrophoresis and immunofixation. (\* excepted for Pseudomonas aeruginosa colonization)

Exclusion criteria

  • Any general condition that predisposes to infections: solid or hematological malignancies, diabetes mellitus, severe alcohol or intravenous drug abuse, chronic liver or kidney failure, human immunodeficiency virus infection, anatomic or functional asplenia, drug-induced 1 neutropenia, or solid organ or hematopoietic stem cell transplantation;
  • Any local predisposing factor to infections: cigarette smoking (> 10 pack-year and/or 5 cigarettes/day), underlying infection (tuberculosis, influenza…), chronic obstructive pulmonary disease, oral, dental or skin conditions favorizing infections, streptococcal skin infections
  • Any other SID or PID diagnosed before inclusion
  • Pregnancy
  • PPV23 administration in the last 2 years (risk of hyporesponsiveness)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

France · 1 center
  • Lille University Hospital — Lille

Identifiers

NCT: NCT05664035 · 2021_0699 · 2022-A00574-39

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗